The one successful report of a BTK inhibitor showing efficacy in RA patients was with fenebrutinib, the most selective BTK inhibitor in this class (Table 4) and was tested over this longer 12 week period (74). The gene discussed is BTK; the disease is rheumatoid arthritis.